Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Other Non Operating Income (2023 - 2026)

Contineum Therapeutics' Other Non Operating Income history spans 4 years, with the latest figure at -$57000.0 for Q1 2026.

  • Quarterly Other Non Operating Income rose 56.15% to -$57000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$92000.0 through Mar 2026, up 68.06% year-over-year, with the annual reading at -$165000.0 for FY2025, 1.23% down from the prior year.
  • Other Non Operating Income came in at -$57000.0 for Q1 2026, down from -$51000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $257000.0 in Q4 2023 to a low of -$167000.0 in Q2 2025.
  • The 4-year median for Other Non Operating Income is -$47000.0 (2024), against an average of -$19923.1.
  • The largest YoY upside for Other Non Operating Income was 638.24% in 2025 against a maximum downside of 2066.67% in 2025.
  • Contineum Therapeutics' Other Non Operating Income stood at $257000.0 in 2023, then tumbled by 118.29% to -$47000.0 in 2024, then fell by 8.51% to -$51000.0 in 2025, then dropped by 11.76% to -$57000.0 in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Other Non Operating Income are -$57000.0 (Q1 2026), -$51000.0 (Q4 2025), and $183000.0 (Q3 2025).